% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Feb 17, 2011 9:08 PM Flag

    Competition update:


    Co reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. The data support the findings that cabozantinib reduces or stabilizes metastatic bone lesions in nearly all patients evaluable by bone scan, reduces bone pain and narcotic analgesic medication and results in an increase in hemoglobin in patients with anemia. The data also suggest that cabozantinib shows an encouraging early signal of durable clinical benefit in both docetaxel-naive and pretreated patients. Safety data are available for the lead in phase of the study for 100 patients with at least 12 weeks of follow-up. The most common >= grade 3 adverse events (AEs), regardless of causality were fatigue (15%), hypertension (8%), PPE syndrome (5%), back pain (3%), decreased appetite, nausea, vomiting, rash, hemorrhage, abdominal pain (each 2%), diarrhea, dyspnea, and cough (each 1%). No cabozantinib-related grade 5 AEs were reported. At least one dose reduction was reported in 51% of patients.

0.47Sep 29 4:00 PMEDT